AR123862A1 - Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares - Google Patents
Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades ocularesInfo
- Publication number
- AR123862A1 AR123862A1 ARP210102899A ARP210102899A AR123862A1 AR 123862 A1 AR123862 A1 AR 123862A1 AR P210102899 A ARP210102899 A AR P210102899A AR P210102899 A ARP210102899 A AR P210102899A AR 123862 A1 AR123862 A1 AR 123862A1
- Authority
- AR
- Argentina
- Prior art keywords
- variable domain
- chain variable
- seq
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Moléculas de unión que se unen específicamente al factor de crecimiento endotelial vascular (VEGF) y al receptor quinasa B de la tropomiosina (TrkB) y a su uso en medicina, composiciones farmacéuticas que lo comprenden y métodos para su uso como agentes para el tratamiento y/o prevención de enfermedades oculares. Reivindicación 1: Una molécula de unión caracterizada porque comprende al menos un sitio de unión al antígeno que se une específicamente al factor de crecimiento endotelial vascular (VEGF) y al menos un sitio de unión al antígeno que se une específicamente al receptor quinasa B de la tropomiosina (TrkB). Reivindicación 28: Un scFv que se une específicamente a TrkB que comprende (i) un dominio variable de cadena ligera que comprende la secuencia de aminoácidos de SEQ ID Nº 213 y un dominio variable de cadena pesada caracterizado porque comprende la secuencia de aminoácidos de SEQ ID Nº 214, o (ii) un dominio variable de cadena ligera que comprende la secuencia de aminoácidos de SEQ ID Nº 215 y un dominio variable de cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 216. Reivindicación 30: Una molécula de anticuerpo que se une específicamente a VEGF caracterizada porque comprende: (i) un dominio variable de cadena ligera que comprende la secuencia de aminoácidos de SEQ ID Nº 189, y un dominio variable de cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 191; o un dominio variable de cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 192; o un dominio variable de cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 194; (ii) un dominio variable de cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 190, y un dominio variable de cadena ligera que comprende la secuencia de aminoácidos de SEQ ID Nº 192; o un dominio variable de cadena ligera que comprende la secuencia de aminoácidos de SEQ ID Nº 193. Reivindicación 32: Una molécula de ácido nucleico aislada caracterizada porque codifica (i) la cadena pesada o el dominio variable de la cadena pesada y/o (ii) la cadena ligera o el dominio variable de la cadena ligera de una molécula de unión de acuerdo con cualquiera de las reivindicaciones 1 a 19. Reivindicación 36: Un vector viral caracterizado porque comprende la molécula de ácido nucleico aislada de acuerdo con cualquiera de las reivindicaciones 32 a 35. Reivindicación 37: Un vector de expresión caracterizado porque comprende una molécula de ácido nucleico de acuerdo con cualquiera de las reivindicaciones 32 a 35. Reivindicación 38: Una célula huésped caracterizada porque está transfectada con un vector de expresión de acuerdo con la reivindicación 37. Reivindicación 39: Un método de fabricación de una molécula de unión de acuerdo con las reivindicaciones 1 a 19, una molécula de unión de TrkB de acuerdo con las reivindicaciones 20 a 27, un scFv de acuerdo con las reivindicaciones 28 a 29 o una molécula de anticuerpo de acuerdo con las reivindicaciones 30 a 31, caracterizado porque comprende (a) cultivar la célula huésped de acuerdo con la reivindicación 38 en condiciones que permitan la expresión de la molécula; y, (b) recuperar la molécula; y opcionalmente (c) purificar y/o modificar y/o formular adicionalmente la molécula. Reivindicación 47: Una composición farmacéutica caracterizada porque comprende un portador farmacéuticamente aceptable y la molécula de unión de acuerdo con cualquiera de las reivindicaciones 1 a 19, la molécula de unión de TrkB de acuerdo con las reivindicaciones 20 a 27, el scFv de acuerdo con las reivindicaciones 28 a 29, o la molécula de anticuerpo de acuerdo con las reivindicaciones 30 al 31.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20203030 | 2020-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR123862A1 true AR123862A1 (es) | 2023-01-18 |
Family
ID=73005392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210102899A AR123862A1 (es) | 2020-10-21 | 2021-10-20 | Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares |
Country Status (7)
Country | Link |
---|---|
US (2) | US20220119536A1 (es) |
EP (2) | EP4232476A2 (es) |
JP (2) | JP2023546229A (es) |
CN (2) | CN117043186A (es) |
AR (1) | AR123862A1 (es) |
TW (1) | TW202233668A (es) |
WO (2) | WO2022084354A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023546229A (ja) * | 2020-10-21 | 2023-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼の疾患の処置のためのアゴニスト性TrkB結合分子 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731A (en) | 1848-08-22 | Elisha k | ||
US168A (en) | 1837-04-17 | Improvement in fire-arms | ||
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
ES2108460T3 (es) | 1993-06-03 | 1997-12-16 | Therapeutic Antibodies Inc | Fragmentos de anticuerpos en terapeutica. |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
EP0979102A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE |
US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2433877C (en) | 2001-01-17 | 2014-11-18 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2003050531A2 (en) | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
EP2336179A1 (en) | 2002-11-08 | 2011-06-22 | Ablynx N.V. | Stabilized single domain antibodies |
PT1639011E (pt) | 2003-06-30 | 2009-01-20 | Domantis Ltd | Anticorpos (dab) de domínio único peguilados |
EP1945671A2 (en) | 2005-10-12 | 2008-07-23 | MorphoSys AG | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
JP5374359B2 (ja) * | 2006-03-17 | 2013-12-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 安定化されたポリペプチド化合物 |
WO2008058127A2 (en) | 2006-11-09 | 2008-05-15 | Irm Llc | Agonist trkb antibodies and uses thereof |
HUE028536T2 (en) | 2008-01-07 | 2016-12-28 | Amgen Inc | Method for producing antibody to FC heterodimer molecules using electrostatic control effects |
US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
UY33707A (es) * | 2010-11-04 | 2012-05-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
JP6959912B2 (ja) | 2015-09-23 | 2021-11-05 | ジェネンテック, インコーポレイテッド | 抗vegf抗体の最適化変異体 |
CN109414501A (zh) | 2016-05-03 | 2019-03-01 | 斯克利普斯研究院 | 用于治疗神经退行性疾病的TrkB激动剂抗体 |
AU2017324983A1 (en) | 2016-09-07 | 2019-04-18 | Saksin Lifesciences Pvt Ltd | Synthetic antibodies against VEGF and their uses |
JP7216424B2 (ja) | 2017-03-15 | 2023-02-01 | チンファ ユニバーシティ | 新規の抗TrkB抗体 |
PE20191758A1 (es) | 2017-03-22 | 2019-12-12 | Genentech Inc | Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares |
US10793634B2 (en) | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
US20220185875A1 (en) | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
JP2020187202A (ja) | 2019-05-13 | 2020-11-19 | キヤノン株式会社 | 画像形成装置 |
JP2023546229A (ja) | 2020-10-21 | 2023-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼の疾患の処置のためのアゴニスト性TrkB結合分子 |
-
2021
- 2021-10-20 JP JP2023524324A patent/JP2023546229A/ja active Pending
- 2021-10-20 US US17/505,763 patent/US20220119536A1/en not_active Abandoned
- 2021-10-20 TW TW110138827A patent/TW202233668A/zh unknown
- 2021-10-20 CN CN202180078806.0A patent/CN117043186A/zh active Pending
- 2021-10-20 WO PCT/EP2021/079010 patent/WO2022084354A1/en active Application Filing
- 2021-10-20 WO PCT/EP2021/079011 patent/WO2022084355A2/en active Application Filing
- 2021-10-20 EP EP21798613.2A patent/EP4232476A2/en active Pending
- 2021-10-20 AR ARP210102899A patent/AR123862A1/es unknown
- 2021-10-20 JP JP2023524323A patent/JP2023546228A/ja active Pending
- 2021-10-20 CN CN202180070390.8A patent/CN116829586A/zh active Pending
- 2021-10-20 US US17/505,672 patent/US12110335B2/en active Active
- 2021-10-20 EP EP21798332.9A patent/EP4232474A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4232476A2 (en) | 2023-08-30 |
CN117043186A (zh) | 2023-11-10 |
WO2022084355A2 (en) | 2022-04-28 |
US20220119535A1 (en) | 2022-04-21 |
CN116829586A (zh) | 2023-09-29 |
US20220119536A1 (en) | 2022-04-21 |
US12110335B2 (en) | 2024-10-08 |
TW202233668A (zh) | 2022-09-01 |
JP2023546229A (ja) | 2023-11-01 |
WO2022084354A1 (en) | 2022-04-28 |
JP2023546228A (ja) | 2023-11-01 |
WO2022084355A3 (en) | 2022-06-02 |
EP4232474A1 (en) | 2023-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
RU2015150149A (ru) | Составы на основе биспецифических антител к il-4/il-13 | |
HRP20210736T1 (hr) | Protutijela anti-htra1 i načini njihove uporabe | |
AR102595A1 (es) | Anticuerpos anti-ang2 y métodos de utilización | |
AR123862A1 (es) | Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares | |
RU2020121533A (ru) | Антагонисты ildr2 и их комбинации | |
PE20240913A1 (es) | Anticuerpos anti-il-2r agonistas y metodos de uso | |
AR123306A1 (es) | Anticuerpos fgfr3 y métodos de uso | |
PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
AR095499A1 (es) | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b | |
AR125488A1 (es) | Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas | |
AR125142A1 (es) | Moléculas de unión terapéuticas | |
CN112996564A (zh) | 靶向il-1r1和nlpr3的双特异性抗体 | |
US10370442B2 (en) | vNAR recombinant monoclonal antibodies that neutralize vascular endophelial growth factor VEGF | |
MX2022000780A (es) | Fragmento fab del anticuerpo anti-vegf humanizado y uso del mismo. | |
AR125857A1 (es) | ANTICUERPOS PARA EL TRATAMIENTO DE a-SINUCLEINOPATÍAS | |
RU2016135418A (ru) | Новый анализ для детектирования периостина человека | |
PE20240086A1 (es) | Anticuerpos anti-cd122 y usos de estos | |
AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
PE20230414A1 (es) | Agentes de fijacion a tie2 y metodos de uso | |
KR20240016991A (ko) | 항-nkg2a 항체 및 조성물 | |
AR122286A1 (es) | Anticuerpos potenciadores del factor h y usos de estos |